行情

KPTI

KPTI

Karyopharm
NASDAQ

实时行情|Nasdaq Last Sale

10.06
-0.67
-6.24%
盘后: 10.07 +0.01 +0.09% 16:11 09/23 EDT
开盘
10.61
昨收
10.73
最高
10.75
最低
9.65
成交量
189.71万
成交额
--
52周最高
18.56
52周最低
3.920
市值
6.23亿
市盈率(TTM)
-2.8332
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

KPTI 新闻

  • 观点:负利率不会很快来到美国
  • 新浪美股.44分钟前
  • 黄金期货周一收高1.1% 白银跃升4.8%
  • 新浪美股.52分钟前
  • 美联储研究报告称市场对利率降至零的预期上升
  • 新浪美股.1小时前
  • 调查:用户对iPhone11不那么感兴趣 等待明年5G机型
  • 新浪美股.2小时前

更多

所属板块

生物技术和医学研究
-0.69%
制药与医学研究
-0.44%

热门股票

名称
价格
涨跌幅

KPTI 简况

Karyopharm Therapeutics Inc. is an oncology-focused pharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. Its selective inhibitor of nuclear export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Its lead compound, XPOVIOTM (selinexor), received accelerated approval from the Food and Drug Administration (FDA), in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. Its XPOVIO is an oral SINE compound, which blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. It is also focused on developing treatments for other diseases, such as Hematologic Malignancies and Solid Tumor Malignancies.
展开

Webull提供Karyopharm Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。